利妥昔单抗联合短周期、高强度方案治疗Burkitt白血病疗效及安全性分析

OBJECTIVE: This study aimed to explore the efficacy and safety of rituximab combined with short-course and intensive regimens in the treatment of adult patients with Burkitt leukemia. METHODS: The clinical data of 11 Burkitt leukemia patients in our hospital from January 30, 2006, to September 12, 2018, were collected. The clinical details, complete remission (CR) rate, overall survival (OS), relapse-free survival (RFS), and adverse events were evaluated. RESULTS: The median age of 11 patients was 34 (15–54) years, of which six were males and five were females (M∶F, 1.2∶1). The median white blood cell (WBC) count was 12.28 (2.21–48.46) ×10(9)/L, and the median blast percent of peripheral blood and bone marrow were 40% (3%–76%) and 84.0% (29.5%–94.5%), respectively. Ten patients were administered with rituximab combined with a short-course and intensive regimens, and two patients underwent autologous hematopoietic stem cell transplantation following consolidation chemotherapy. The CR rate after one cycle of induction therapy was 100%, the four-year OS was 90%, and RFS was 90%. Out of the ten treated patients, only one patient suffered from tumor lysis syndrome during the induction chemotherapy. Consequently, renal function recovered after hemodialysis and other treatments. The regimen is safe with no treatment-related deaths. CONCLUSION: Rituximab combined with short-course and intensive chemotherapy regimens is effective and well-tolerated in adult Burkitt leukemia.